logo
  

Biogen Submits Final Protocol For Envision Trial Of Aduhelm On Alzheimer's Disease

Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug Administration for review and approval.

The company expects the first patient to enter screening in May 2022 and the trial's primary completion approximately four years after the study begins.

The confirmatory trial is a requirement based on FDA's accelerated approval of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease.

The study will be a global, placebo-controlled trial, aiming to enroll around 1,500 patients with early Alzheimer's disease and confirmation of amyloid beta pathology.

The company has also reaffirmed the trial's goal of recruiting at least 18 percent of patients in the U.S. from Black/African American and Latino communities.

Aduhelm is indicated for the treatment of Alzheimer's disease. Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Aduhelm is a monoclonal antibody directed against amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT